Journal of Hepatology最新文献

{"title":"Corrigendum to “Association of metabolic signatures of air pollution with MASLD: Observational and Mendelian randomization study” [J Hepatol (2025) 10.1016/j.jhep.2024.09.033]","authors":"Shanshan Ran, Jingyi Zhang, Fei Tian, Zhengmin (Min) Qian, Shengtao Wei, Yuhua Wang, Ge Chen, Junguo Zhang, Lauren D. Arnold, Stephen Edward McMillin, Hualiang Lin","doi":"10.1016/j.jhep.2025.04.001","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.001","url":null,"abstract":"We appreciate the letter by Drs Zhao and Zhao highlighting an inconsistency in data presentation in the graphical abstract of our article. In Step 2, the forest plot on the left was meant to display data on the association between air pollutants and MASLD. This has now been corrected in the published version. We apologize for any inconvenience caused.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"8 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Of mice and men: Unlocking precision medicine for liver cancer","authors":"David J. Pinato","doi":"10.1016/j.jhep.2025.03.025","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.03.025","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>Whilst widening adoption of next-generation sequencing has redefined management of most cancers by allowing identification of molecularly defined patient subgroups matched with targeted therapeutic options, hepatocellular carcinoma (HCC) has remained virtually untouched by the molecular revolution of cancer care.¹The extent of this unmet need is perhaps epitomized by considering how the anatomic proximity of biliary and hepatocellular tumours contrasts with the abyssal molecular distance</section></section><section><section><h2>Objectives, methods, and findings</h2>By selecting somatic mutational events for their pro-tumorigenic potential in HCC, Mueller and collaborators used cancer genome atlas data to design highly hepato-specific adenoviral vectors capable of transfecting adult mouse hepatocytes in an immunocompetent environment. Each resulting cohort of genetically modified mice was characterized by the presence of tumours harbouring one or more distinctive initiating molecular events such as <em>TP53, CDKN2A, PTEN, AXIN1, BAP1</em> loss of function mutations</section></section><section><section><h2>Significance of findings</h2>The extensive body of pre-clinical work published by Mueller <em>et al.</em> represents an important advance in therapeutic drug development for HCC. First, discovery of high-fidelity pre-clinical models with improved resemblance to human HCC is posited to improve our understanding of mechanisms of efficacy and resistance to novel systemic treatments for liver cancer. Not all therapeutic combinations can be directly tested upfront in patients, where surrogate measures of anti-tumour efficacy often</section></section><section><section><h2>Financial support</h2>The author did not receive any financial support to produce this manuscript.</section></section><section><section><h2>Conflict of interest</h2>DJP received lecture fees from ViiV Healthcare, Bayer Healthcare, Roche, BMS, Falk; travel expenses from BMS, MSD and Bayer Healthcare; consulting fees for Mina Therapeutics, Eisai, H3B, Roche, Boston Scientific, Astra Zeneca, DaVolterra; received research funding (to institution) from MSD, GSK, BMS.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section><section><section><h2>Acknowledgements</h2>The author would like to acknowledge the Imperial College National Institute for Health Research Biomedical Research Centre and the Imperial Experimental Cancer Medicine Centre.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"17 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease","authors":"Seogsong Jeong","doi":"10.1016/j.jhep.2025.04.023","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.023","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Study concept and design: SJManuscript writing: SJ</section></section><section><section><h2>Declaration of generative AI and AI-assisted technologies in the writing process</h2>The author used ChatGPT in the proofreading of this manuscript. After using this tool, the author reviewed and edited the content and takes full responsibility for the content of the publication.</section></section><section><section><h2>Financial support</h2>This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (RS-2025-00523629).</section></section><section><section><h2>Declaration of Competing Interest</h2>None.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"67 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk stratification beyond fibrosis in SLD: The case for lifestyle-responsive prognostic tools","authors":"Fredrik Åberg, Juho V. Asteljoki, Panu K. Luukkonen","doi":"10.1016/j.jhep.2025.04.024","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.024","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>FÅ; is the lead author and the guarantor. All authors contributed to study conceptualization. FÅ; did the formal analyses and wrote the first draft. All authors reviewed, critically revised, and approved the final manuscript.</section></section><section><section><h2>Data availability statement (delete if not applicable)</h2>Data from the UK Biobank are available for researchers through application (<span><span>https://www.ukbiobank.ac.uk/</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>)</section></section><section><section><h2>Financial support</h2>Dr. Åberg was supported by the Academy of Finland (#338544), Sigrid Jusélius Foundation, Wilhelm and Else Stockmann Foundation, Finska Läkaresällskapet, and Medicinska Understödsföreningen Liv och Hälsa. Dr. Luukkonen was supported by the Academy of Finland (350545), Sigrid Jusélius Foundation, Novo Nordisk Foundation (NNF22OC0074397), Emil Aaltonen Foundation, Finnish Medical Foundation, Wilhelm and Else Stockmann Foundation, Early Career Investigator fund of the University of Helsinki, and</section></section><section><section><h2>Declaration of Competing Interest</h2>FÅ declares consulting fees from Boehringer-Ingelheim, Takeda, Astra Zeneca, and Ipsen; payment for lectures from Abbvie, Sandoz, Siemens Healthineers, Astellas and Norgine; all outside the current work. PKL declares consulting fees from AstraZeneca, Boehringer-Ingelheim, and Bluejay Therapeutics; payment for lectures from Johnson &amp; Johnson, Novartis, and Sandoz; all outside the current work. JVA declares no competing interests.Please refer to the accompanying ICMJE disclosure forms for further</section></section><section><section><h2>Acknowledgments</h2>This study was conducted using the UK Biobank Resource (application number 62797). Copyright © (2023), NHS England. Re-used with the permission of the NHS England and UK Biobank. All rights reserved. This work uses data provided by patients and collected by the NHS as part of their care and support. This research used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"30 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MASLD and non-liver-related mortality: association, independent association and causality","authors":"George N. Ioannou","doi":"10.1016/j.jhep.2025.04.020","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.020","url":null,"abstract":"&lt;h2&gt;Section snippets&lt;/h2&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;MASLD and non-liver-related mortality: the difference between association, independent association and causality&lt;/h2&gt;Patients with MASLD have a high prevalence of cardiometabolic risk factors. Indeed, the new definition of MASLD formally requires the presence of at least one cardiometabolic risk factor, including overweight/obesity, diabetes or impaired fasting glucose, hypertension, hypertriglyceridemia or dyslipidemia[1]. Therefore, it should not be surprising that patients with MASLD experience high mortality from adverse cardiovascular events and non-hepatic malignancies related to these cardiometabolic&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Cause-specific mortality in MASLD patients from Swedish registries: implications of study by Wester et al for multidisciplinary care and risk stratification of MASLD patients&lt;/h2&gt;In this issue of the Journal of Hepatology, Wester et al. identified 13,099 patients from Sweden who were first documented to have ICD-10 codes for MASLD ((K76.0 and K75.8) in the Swedish National Patient Register of inpatient and specialized outpatient care from 2002-2020[2]. These MASLD patients were compared to controls identified from the general population, matched for age, sex, municipality, and calendar year and additionally adjusting for country of birth and modified Charlson&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Caution in interpreting the associations between MASLD and excess non-liver-related mortality reported by Wester et al: selection and confounding biases&lt;/h2&gt;The associations reported by Wester et al. between MASLD and excess non-liver-related mortality, must be interpreted in the context of two important potential sources of bias:&lt;ul&gt;&lt;li&gt;&lt;span&gt;a.&lt;/span&gt;&lt;span&gt;&lt;u&gt;Selection bias&lt;/u&gt;. Cases of MASLD were derived from inpatient and specialized outpatient clinic records of Sweden (“Swedish National Patient Register”) who had documentation of ICD-10 codes for fatty liver disease. This is likely to select for a small subset of MASLD cases with more advanced disease. The fact that only 13,099&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Associations of MASLD with non-liver-related mortality: comparison of three different studies&lt;/h2&gt;While Wester et al. and a recent study by Simon et al.[3] reported significantly higher non-liver-related mortality in patients with MASLD, a study by Younossi et al.[4] found no association between MASLD and all-cause, cardiovascular or cancer-related mortality (Table 2). Why did the studies reach such different conclusions?Comparison of the selection criteria for cases and controls and different levels of adjustment for confounders in the three studies likely explain the different results and&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Conclusions&lt;/h2&gt;The study by Wester et al. nicely highlights the high cardiovascular and cancer-related mortality of patients with MASLD. Most patients with MASLD will die of cardiovascular disease ","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"28 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma","authors":"Mathew Vithayathil, Deniz Koku, Claudia Campani, Jean-Charles Nault, Olivier Sutter, Nathalie Ganne Carrié, Eric O. Aboagye, Rohini Sharma","doi":"10.1016/j.jhep.2025.04.017","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.017","url":null,"abstract":"<h3>Background</h3>Atezolizumab plus bevacizumab (A/B) is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Only a small proportion of patients respond to treatment. This study integrated radiomic and clinical data derived from routine pre-treatment imaging to predict outcomes after immunotherapy.<h3>Methods</h3>152 patients from two international centres receiving A/B were retrospectively reviewed. Deep learning autosegmentation generated whole liver masks from pre-treatment CTs. Radiomic features combined with clinical variables were used to predict 12-month mortality post A/B. Radiomic and integrated radiomic-clinical models were developed using 7 machine learning models in combination with 13 feature selection techniques in the Imperial College London (ICL) cohort. K-means clustering identified high- and low-risk groups and predicted overall survival (OS), progression-free survival (PFS) and response. Model performance was assessed in the independent Assistance Publique-Hôpitaux de Paris (AP-HP) cohort.<h3>Results</h3>The integrated radiomic-clinical model outperformed BCLC stage (AUC 0.61, <em>p</em>&lt;0.001) and ALBI grade (AUC 0.48, <em>p</em>&lt;0.001) in ICL (AUC 0.89, 95% CI 0.75-0.99) and AP-HP (AUC 0.75, 95% CI 0.64-0.85) cohorts. Integrated model-stratified high-risk patients had significantly shorter median OS (ICL: 5.6 months vs. 28.2 months; <em>p</em>&lt;0.001; AP-HP: 5.8 months vs. 15.7 months; <em>p</em>&lt;0.001) and PFS (ICL: 2.4 months vs. 14.6 months; <em>p</em>&lt;0.001; AP-HP: 2.1 months vs. 6.1 months; <em>p</em>=0.046). Low-risk patients had significantly higher ICI response rates compared to high-risk patients (35.6% vs. 21.4%; <em>p</em>=0.038). In multivariable analysis, radiomic group was the strongest predictor of OS (HR 3.22, 95% CI 1.99-5.20; <em>p</em>&lt;0.001) and PFS (HR 1.82, 95% CI 1.18-2.80; <em>p</em>=0.010).<h3>Conclusion</h3>Radiomic-based models predict survival outcomes and response to immunotherapy in patients with advanced HCC. Deep learning in combination with machine learning can stratify patients and allows for precision treatment strategies.<h3>Impact and Implications</h3>There is a lack of prognostic markers predicting survival and response after immunotherapy in hepatocellular carcinoma. This study used deep learning and machine learning to develop and validate an integrated radiomic-clinical model which can predict survival and response to atezolizumab plus bevacizumab from pre-treatment imaging. Radiomic-based machine learning models can risk-stratify advanced HCC patients receiving atezolizumab plus bevacizumab.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"122 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Albumin infusion in Hepatorenal Syndrome-Acute Kidney Injury: new evidence challenges recent consensus.","authors":"Paolo Angeli, Christian Labenz, Salvatore Piano, Adrià Juanola, Aleksander Krag, Paolo Caraceni, Jonel Trebicka, Rakhi Maiwall, Virendra Singh, Elisa Pose, Carmine Gambino, Sebastian Marciano, Peter R. Galle, Shiv K. Sarin, Pere Ginès, Patrick S. Kamath","doi":"10.1016/j.jhep.2025.04.011","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.011","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>The new evidence in the management of HRS-AKI in patients with cirrhosis</h2>The conclusions of the ADQI and ICA Joint Multidisciplinary Consensus Meeting were published in the Journal of Hepatology in July 2024 (2).Subsequently, a prospective observational study was published in the same Journal in September 2024 analyzing the effectiveness of the algorithm proposed by the EASL CPGs in the management of AKI in patients with cirrhosis and a letter as explanatory corollary by the Barcelona research team led by Pere Ginès 3, 4. The main content of these papers can be</section></section><section><section><h2>Discussion</h2>To rectify any misunderstanding, it is accepted that at the time of developing the position paper of the ADQI and ICA the results of this research group have not yet been published. This being said, the issue of volume expansion in the management of AKI should be discussed. Without any doubt, the need for assessing the patient volume status and thus the real need for volume replacement, and the need to standardize methods to assess volume status and monitor the response to volume replacement is</section></section><section><section><h2>Conclusions</h2>The application of the EASL AKI algorithm, derived from the previous statements proposed by the ICA, is associated with very good response rates and does not significantly delay initiation of therapy with terlipressin. The use of 48-hour albumin infusion and the use of the old diagnostic criteria to differentiate HRS-AKI and ATN-AKI are both essential components of the algorithm. There is need for studies addressing the important questions on the dose and duration of albumin treatment to</section></section><section><section><h2>Authors’ contribution</h2>Conceptualization (PA, SP, PC, PG, PK), drafting of the manuscript (PA), revision for important intellectual content and approval of the final manuscript (all authors).</section></section><section><section><h2>Funding</h2>No specific funding supported this paper.</section></section><section><section><h2>Declaration of Competing Interest</h2><strong>PA</strong> received grant/research support from Grifols and CSL Behring; held a patent with Biovie; served as consulting for Sequana Medical and BioMarin. <strong>CL</strong> received speaker fees from CSL Behring. <strong>SP</strong> received grant/research support from Italian Minstry of Health, European Union; speaker fees from Ferring, Grifols, MEDSCAPE; served as consulting for Boehringer Ingelheim. <strong>AK</strong> received grant/research support from European Union, Novo Nordisk Foundation, AstraZeneca; speaker fees from Norgine, Siemens,</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"28 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rat hepacivirus model to aid hepatitis C viral vaccine development ?","authors":"Michael Houghton","doi":"10.1016/j.jhep.2025.04.016","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.016","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"34 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing our understanding of recompensated cirrhosis - the new “holy grail” of decompensated cirrhosis","authors":"Thomas REIBERGER, Benjamin MAASOUMY","doi":"10.1016/j.jhep.2025.04.014","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.04.014","url":null,"abstract":"No Abstract","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"37 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Register now for the EASL Congress 2025, 7-10 May in Amsterdam!","authors":"","doi":"10.1016/S0168-8278(25)00178-3","DOIUrl":"10.1016/S0168-8278(25)00178-3","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 5","pages":"Page ii"},"PeriodicalIF":26.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143832077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}